Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease

Abstract

Infliximab is safe and effective in the short-term treatment of medically refractory pediatric Crohn's disease. More importantly, there is a remarkably prolonged duration of response after infliximab therapy in children with early compared to late Crohn's disease.